Evidence map›Paper›PMID 42549887›Full record

ArticleCancer medicine2026

Feasibility of Integrating a Standardized Psychosocial Follow-Up After Childhood Cancer-An Interim Analysis of the LE-Na Study.

Madelaine Sleimann, Magdalena Balcerek, Gabriele Calaminus, Martina B Schaefer, Rainer John, Judith Lohse, Sonja Schuster, Teresa Halbsguth, Alexander Puzik, Franziska Wolters and 13 more

Abstract read
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Madelaine SleimannDepartment of Pediatrics, University Hospital Schleswig-Holstein, Lübeck, Germany.ORCID https://orcid.org/0009-0004-0251-3958
Magdalena BalcerekDepartment of Oncology, Hepatology and Pneumology, University Hospital Leipzig and University Cancer Center Leipzig, Leipzig, Germany.
Gabriele CalaminusClinic for Pediatric Hematology and Oncology, Center for Pediatric and Adolescent Medicine, University Hospital Bonn, Bonn, Germany.
Martina B SchaeferClinic for Pediatric Hematology and Oncology, Center for Pediatric and Adolescent Medicine, University Hospital Bonn, Bonn, Germany.
Rainer JohnDepartment of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Judith LohseClinic and Polyclinic for Pediatrics and Adolescent Medicine, Department of Pediatric Hematology and Oncology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Sonja SchusterDepartment of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Teresa HalbsguthDepartment of Medicine II, Hematology and Oncology, University Cancer Center (UCT) Frankfurt, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
Alexander PuzikDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, Children's Hospital, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Franziska WoltersDepartment of Hematology and Oncology With Section Pneumology, Hubertus Wald Tumor Center-University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Jörg FaberDepartment of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center Mainz, Mainz, Germany.
Irene von LuettichauCenter for Pediatrics and Adolescent Medicine, a Collaboration Between Munich Clinic and TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Munich, Germany.
Sophia HömbergDepartment of Pediatric Hematology and Oncology, Asklepios Children's Hospital Sankt Augustin, Sankt Augustin, Germany.
Sebastian MichaelisDepartment I of Pediatric Hematology and Oncology, University Children's Hospital Tübingen, Tübingen, Germany.
Melanie KaiserDepartment of Epidemiology of Childhood Cancer (EpiKiK)/German Childhood Cancer Registry (DKKR), Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Desiree GrabowDepartment of Epidemiology of Childhood Cancer (EpiKiK)/German Childhood Cancer Registry (DKKR), Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Inke KönigInstitute of Medical Biometry and Statistics (IMBS), University of Luebeck, University Hospital Schleswig-Holstein, Lübeck, Germany.
Anke NeumannSection for Clinical Research IT (SKFIT), Institute of Medical Biometry and Statistics (IMBS), University of Luebeck and University Hospital Schleswig-Holstein, Lübeck, Germany.
Ann-Kristin Kock-SchoppenhauerSection for Clinical Research IT (SKFIT), Institute of Medical Biometry and Statistics (IMBS), University of Luebeck and University Hospital Schleswig-Holstein, Lübeck, Germany.
Celina ArendtDepartment of Pediatrics, University Hospital Schleswig-Holstein, Lübeck, Germany.
Thorsten LangerDepartment of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.ORCID https://orcid.org/0000-0002-7047-2957
Katja BaustClinic for Pediatric Hematology and Oncology, Center for Pediatric and Adolescent Medicine, University Hospital Bonn, Bonn, Germany.
Judith GebauerDepartment of Pediatrics, University Hospital Schleswig-Holstein, Lübeck, Germany.

Funding

H.W. & J. Hector Stiftung M 2117
6 · The paper itself

Abstract

backgroundMany childhood and adolescent cancer survivors suffer from late effects that impair quality of life and life expectancy. However, only an estimated 5% of > 47,000 survivors in Germany receive adequate long-term follow-up (LTFU) care. The LE-Na (Evaluation and implementation of multidisciplinary, standardized, guideline-based long-term follow-up care for adult survivors of childhood cancer in Germany) study aims to address this care gap. Our interim analysis compares three recruitment and information pathways and provides information on the feasibility and acceptance of a guideline-based psychosocial screening.

methodsOver the total study period of 5 years, 5000 survivors without previous LTFU care are systematically invited to specialized LTFU clinics in Germany: (1) through the German Childhood Cancer Registry (GCCR), (2) during transition from pediatric to adult care, and (3) via media presence. Longitudinal sociodemographic, medical, and psychosocial data are documented in an online database. Follow-up intervals are based on therapy-associated risk for late effects: annually (high risk), biannually (medium risk), or every 5 years (low risk).

resultsBy the time of our interim analysis, 300 survivors with completed data documentation had been enrolled: 121 (40.3%) were recruited via GCCR invitations, 155 (51.7%) through a structured transition, and 24 (8%) via media presence. Nearly half (131/300; 43.7%) were at high risk for late effects. Almost all (299/300, 99.7%) completed psychosocial screening. A Distress-Thermometer score of ≥ 5 was found in half of the participants (146/299; 48.8%), indicating relevant psychosocial distress.

conclusionThrough the different recruitment methods, survivors with a high risk for late effects were particularly encouraged to accept the LTFU care offer. Integrating a psychosocial screening is feasible and confirms survivors' distress.

trial registrationDRKS identifier: DRKS00033303.

Indexed as

Cancer SurvivorsNeoplasmsAdolescentAdultChildChild, PreschoolFeasibility StudiesFemaleFollow-Up StudiesGermanyHumansMaleQuality of LifeRegistriesYoung Adultchildhood cancer survivorslate effectslong‐term follow‐upmental healthpsychosocial well‐beingquality of life

Identifiers

PMID42549887
PMCPMC13435696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.